Month: July 2020

Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccinePromising vaccine candidate selected by U.S. government’s Operation Warp SpeedU.S. government to provide funding up to $2.1 billion for development, including clinical trials and manufacturing scale-up, and delivery of an initial 100 million dosesOngoing discussions with the European Commission, with France and Italy on the negotiation team, and other governments to ensure global access to a novel coronavirus vaccinePARIS and LONDON – July 31, 2020 – Sanofi and GSK today announce a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine.The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant...

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD         Oxford, UK – 31st July, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a three year Clinical Supply Agreement (“CSA”) with a wholly-owned subsidiary of Axovant Gene Therapies Ltd. (“Axovant”) (Nasdaq: AXGT). The CSA builds on the worldwide license agreement signed between the two companies in June 2018 for the Parkinson’s disease gene therapy program OXB-102, now called AXO-Lenti-PD.Under the terms of the CSA, Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD, a clinical-stage gene therapy product to treat moderate to severe...

NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) — Today, Nasdaq (Nasdaq: NDAQ) announced that Tradeweb Markets (Nasdaq: TW), a leading global operator of electronic marketplaces for fixed income products and derivatives, has selected Nasdaq to provide its Market Surveillance solution for monitoring US Treasuries and Mortgage-Backed Securities trading on Dealerweb, and Swaps trading on DW SEF.The SaaS-deployed technology will provide Tradeweb with a fully integrated platform with robust and flexible market surveillance workflows to manage cross-market, cross-asset, and multi-venue surveillance, supported by market-leading analysis and visualization tools. The tools will effectively monitor billions of trading messages in real-time or historically in a simplified way by distilling complex information into user-friendly formats.“As markets...

Sanofi et GSK sélectionnés par le programme Operation Warp Speed pour fournir 100 millions de doses du vaccin contre la COVID-19 au gouvernement des États-UnisUn candidat-vaccin prometteur sélectionné par le programme Operation Warp Speed du gouvernement américain.Le gouvernement américain va fournir jusqu’à 2,1 milliards de dollars pour le développement, la conduite des essais cliniques et l’augmentation des capacités de production et la fourniture d’un lot initial de 100 millions de dosesDiscussions en cours avec la Commission européenne, avec la France et l’Italie dans l’équipe de négociation, et d’autres gouvernements pour assurer l’accès mondial à un nouveau vaccin contre le coronavirusPARIS et LONDRES – Le 31 juillet 2020 – Sanofi et GSK annoncent aujourd’hui la mise en place d’une collaboration avec le gouvernement...

PERRYSBURG, Ohio, July 31, 2020 (GLOBE NEWSWIRE) — FOR IMMEDIATE RELEASE   O-I Glass, Inc. (NYSE: OI) today announced it completed the sale of its Australia and New Zealand (ANZ) business unit to Visy Industries.  Gross proceeds approximated AUD $947 million including a related sale-leaseback agreement which approximated AUD $214 million. Based on recent currency exchange rates, gross proceeds represented approximately USD $677 million. Approximately 95 percent of proceeds are being received at time of closing and the remaining balance will be paid within 12 months of closing without conditions precedent. Net proceeds will be principally used to reduce debt.O-I ANZ is the largest manufacturer of glass bottles and containers in Australia and New Zealand and the business generated sales of approximately AUD $754 million and EBITDA of...

NEW YORK and BASEL, Switzerland, July 31, 2020 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, announced today that its subsidiary has signed a three-year Clinical Supply Agreement (“CSA”) with Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group. The CSA builds on the worldwide license agreement signed between the two companies in June 2018 for the Parkinson’s disease gene therapy program OXB-102, now called AXO-Lenti-PD.Under the terms of the CSA, Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD, a clinical-stage gene therapy product to treat moderate to severe Parkinson’s Disease based on Oxford Biomedica’s LentiVector® platform....

HOUSTON, July 31, 2020 (GLOBE NEWSWIRE) — W&T Offshore, Inc. (NYSE: WTI) today announced the timing of its second quarter 2020 earnings release and conference call.The Company said it will issue its second quarter 2020 earnings release on Wednesday, August 5, 2020, after the close of trading and host a conference call to discuss financial and operational results on Thursday, August 6, 2020, at 11:00 a.m. Central Time (12:00 pm Eastern Time.)Interested parties may participate by dialing (844) 739-3797.  International parties may dial (412) 317-5713.  Participants should request to be joined to the “W&T Offshore, Inc. Conference Call.”  This call will also be webcast and available on W&T Offshore’s website at www.wtoffshore.com under “Investors.”  An audio replay will be available on the Company’s website following...

Continuing to provide critical support to Canadians and our communities during the COVID-19 pandemic; responding dynamically through exceptional operational execution, providing innovative services and solutions for our customers Consolidated revenue growth of 3.6 per cent and EBITDA decline of 2.9 per cent, combined with healthy free cash flow growth of more than 57 per cent to $511 million, reflective of our team’s resiliency in a challenging and rapidly changing operating environmentDelivered industry-leading customer growth of 141,000 net additions while maintaining the safety and well-being of our customers and team members; leveraging our digital capabilities and demonstrating the efficacy of our longstanding strategic focus on providing the best-in-class customer experience over our world-leading network, buttressed by our leading...

Maintien du soutien essentiel offert aux Canadiens et aux collectivités durant la pandémie de COVID-19; réponse dynamique marquée par une exécution opérationnelle exceptionnelle et prestation de solutions et de services novateurs aux clients Croissance de 3,6 pour cent des produits d’exploitation consolidés, recul de 2,9 pour cent du BAIIA et saine croissance de plus de 57 pour cent du flux de trésorerie disponible, qui s’est chiffré à 511 millions de dollars, ce qui témoigne de la résilience de notre équipe dans un environnement opérationnel difficile qui évolue rapidementMeilleur résultat de l’industrie en matière de croissance de la clientèle, soit 141 000 ajouts nets, tout en veillant au maintien de la sécurité et du mieux-être des clients et des membres de l’équipe; utilisation de nos capacités numériques et confirmation de l’efficacité...